Page M J, Dreese J C, Poritz L S, Koltun W A
Department of Surgery, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey 17033-0850, USA.
Dis Colon Rectum. 1998 May;41(5):619-23. doi: 10.1007/BF02235271.
Cytomegalovirus infection causing symptomatic enteritis is most usually associated with immunosuppressed transplant patients or patients positive for human immunodeficiency virus. Most reports studying this illness are small and do not clearly define the risk factors or mortality rates.
The present study retrospectively reviewed the charts of 67 patients with biopsy-proven cytomegalovirus enteritis (esophageal, gastric, small bowel, and colonic) to define and to investigate factors that influence survival. Patients were classified into four groups based on underlying medical condition: 1) patients positive for human immunodeficiency virus; 2) transplant patients receiving immunosuppressive medications; 3) immunosuppressed nontransplant patients; and 4) otherwise healthy individuals. Mortality rates based on underlying medical condition, location of intestinal cytomegalovirus infection, cytomegalovirus therapy, age, and average days to institution of treatment were defined and statistically assessed.
Mortality was significantly greater in the normal patient group (80 percent) than in the transplant (21 percent), other immunosuppressed (44 percent), or human immunodeficiency virus-positive (75 percent) groups (P = 0.0006, Cochran-Mantel-Haenszel statistics). There was no difference in mortality based on intestinal location of disease or treatment modality (surgery, medical therapy, or both). Cohorts of patients older than 65 years had a statistically higher mortality rate vs. those younger than 65 years old (68 vs. 38 percent; P = 0.05, Cochran-Mantel-Haenszel statistics). Statistically increased mortality was also associated with increased time from hospital admission to institution of cytomegalovirus treatment, whether therapy was medication alone or medication and surgery (P < 0.05, exact Wilcoxon's test).
巨细胞病毒感染导致的症状性肠炎通常与免疫抑制的移植患者或人类免疫缺陷病毒阳性患者相关。大多数研究这种疾病的报告规模较小,且未明确界定危险因素或死亡率。
本研究回顾性分析了67例经活检证实为巨细胞病毒肠炎(累及食管、胃、小肠和结肠)患者的病历,以确定并研究影响生存的因素。根据基础疾病状况将患者分为四组:1)人类免疫缺陷病毒阳性患者;2)接受免疫抑制药物治疗的移植患者;3)免疫抑制的非移植患者;4)其他健康个体。根据基础疾病状况、肠道巨细胞病毒感染部位、巨细胞病毒治疗情况、年龄以及开始治疗的平均天数确定死亡率,并进行统计学评估。
正常患者组的死亡率(80%)显著高于移植患者组(21%)、其他免疫抑制患者组(44%)或人类免疫缺陷病毒阳性患者组(75%)(P = 0.0006, Cochr an-Mantel-Haenszel统计学方法)。基于疾病的肠道位置或治疗方式(手术、药物治疗或两者皆用)的死亡率无差异。65岁以上患者队列的死亡率在统计学上高于65岁以下患者(68%对38%;P = 0.05, Cochr an-Mantel-Haenszel统计学方法)。无论治疗是仅用药物还是药物与手术联合,从入院到开始巨细胞病毒治疗的时间增加也与统计学上死亡率增加相关(P < 0.05,确切Wilcoxon检验)。
1)致命性巨细胞病毒肠炎可发生在通常未被认为有该疾病风险的患者群体中,包括正常个体。2)巨细胞病毒肠炎的死亡率与65岁以上年龄以及治疗开始时间增加呈负相关,但不受感染的解剖部位或特定治疗形式的影响。矛盾的是,在本研究中,正常患者的死亡率最高,我们将其归因于怀疑指数低和治疗相对较晚开始。